Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-12-15 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire du tolébrutinib dans la sclérose en plaques secondaire progressive non-récurrente
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi regarding a regulatory update from the FDA concerning the drug tolebrutinib. It discusses the status of a regulatory submission and potential delays in the review process. This type of announcement regarding regulatory status, clinical trial updates, or drug approval processes is classified as a Regulatory Filing (RNS) as it does not fit into specific categories like financial reports, M&A, or shareholder voting results.
2025-12-15 French
6-K
Foreign Filer Report
2025-12-12 English
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi announcing the regulatory approval of two pharmaceutical products (Qfitlia and Cablivi) by the National Medical Products Administration (NMPA) in China. It details the clinical background, efficacy data, and strategic importance of these approvals. As it is a general regulatory announcement regarding company operations and product approvals that does not fit into specific financial reporting categories like 10-K, ER, or IR, it is classified as a Regulatory Filing (RNS).
2025-12-11 English
Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing the regulatory approval of two drugs (Qfitlia and Cablivi) by the NMPA in China. It details the clinical background, therapeutic benefits, and strategic importance of these approvals for the company's rare disease portfolio. As it is a general corporate announcement regarding business operations and regulatory milestones that does not fit into specific financial reporting or governance categories, it is classified as a Regulatory Filing (RNS).
2025-12-11 French
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is a formal declaration of share buyback transactions ('Déclaration des transactions sur actions propres') by Sanofi. It provides a detailed breakdown of daily aggregated volumes and individual transaction records, including timestamps, prices, and quantities, in compliance with market regulations (MAR art.5). This fits the definition of 'Transaction in Own Shares' (POS).
2025-12-08 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the purchase of its own shares (share buyback) over a specific period (01 December 2025 to 05 December 2025). It includes detailed transaction tables, broker information, and references to Market Abuse Regulation (MAR) article 5. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-12-08 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.